The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) Trial study design: Advancing the active-control evaluation of second-generation drug-eluting stents

American Heart Journal

Volumn 153, Issue 5, 2007, Pages 743-748

  Wang, Tracy Y ^a   Hasselblad, Vic ^a   Peterson, John L ^a   Wijns, William ^b   Parhizgar, Azin ^d   Kereiakes, Dean J ^c   Krucoff, Mitchell W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CARDIOVASCULAR CENTER   (Belgium)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d Conor Medsystems Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT; PACLITAXEL;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; STATISTICAL ANALYSIS;

CHROMIUM ALLOYS; CORONARY RESTENOSIS; DATA INTERPRETATION, STATISTICAL; DRUG DELIVERY SYSTEMS; HUMANS; PACLITAXEL; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; RISK; SINGLE-BLIND METHOD; STENTS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 34247131676     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.02.015     Document Type: Article

References (27)

1. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
2. Stone G.W., Ellis S.G., Cox D.A., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
3. Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Krucoff MW. Post-market evaluation of breakthrough technologies. J Am Coll Cardiol [in press].
4. Kereiakes D.J., Kuntz R.E., Mauri L., et al. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 45 (2005) 1206-1212
5. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
6. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
7. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
8. Rao S.V., Shaw R.E., Brindis R.G., et al. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97 (2006) 1478-1481
9. Serruys P.W., Sianos G., Abizaid A., et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46 (2005) 253-260
10. Dawkins K.D. European pivotal trial with the CoStar stent loaded with an antiproliferative for restenosis trial (EuroSTAR): final 12 month results. Presented at World Congress of Cardiology, Barcelona, Spain (2006)
11. Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
12. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
13. Muni N.I., Califf R.M., Foy J.R., et al. Coronary drug-eluting stent development: issues in trial design. Am Heart J 149 (2005) 415-433
14. The Stent or Surgery (SOS) Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 360 (2002) 965-970
15. Mehran R., Dangas G.D., Kobayashi Y., et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 43 (2004) 1348-1354
16. Rodriguez A., Bernardi V., Navia J., et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 37 (2001) 51-58
17. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
18. Bucher H.C., Guyatt G.H., Griffith L.E., et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50 (1997) 683-691
19. Hasselblad V., and Kong D.F. Statistical methods for comparison to placebo in active-control trials. Drug Inf J 35 (2001) 435-449
20. Hauck W.W., and Anderson S. Some issues in the design and analysis of equivalence trials. Drug Inf J 33 (1999) 109-118
21. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics 55 (1999) 484-487
22. Grube E., Silber S., Hauptmann K.E., et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 96 (2005) 79-82
23. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
24. Mauri L., Orav E.J., and Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 111 (2005) 3435-3442
25. Muni N.I., and Gross T.P. Problems with drug-eluting coronary stents-the FDA perspective. N Engl J Med 351 (2004) 1593-1595
26. Rupprecht H.J., Espinola-Klein C., Erbel R., et al. Impact of routine angiographic follow-up after angioplasty. Am Heart J 136 4 Pt 1 (1998) 613-619
27. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613